Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1233192.RAB3xIVwXxlnFT-LkfZes9KxI8_b6hJR5TYxu0SllofaY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1233192.RAB3xIVwXxlnFT-LkfZes9KxI8_b6hJR5TYxu0SllofaY130_assertion type Assertion NP1233192.RAB3xIVwXxlnFT-LkfZes9KxI8_b6hJR5TYxu0SllofaY130_head.
- NP1233192.RAB3xIVwXxlnFT-LkfZes9KxI8_b6hJR5TYxu0SllofaY130_assertion description "[The clinical efficacy of the ALK inhibitor, crizotinib, lags behind expectations for treating MYCN-amplified, ALK-mutant neuroblastoma, a deadly childhood cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1233192.RAB3xIVwXxlnFT-LkfZes9KxI8_b6hJR5TYxu0SllofaY130_provenance.
- NP1233192.RAB3xIVwXxlnFT-LkfZes9KxI8_b6hJR5TYxu0SllofaY130_assertion evidence source_evidence_literature NP1233192.RAB3xIVwXxlnFT-LkfZes9KxI8_b6hJR5TYxu0SllofaY130_provenance.
- NP1233192.RAB3xIVwXxlnFT-LkfZes9KxI8_b6hJR5TYxu0SllofaY130_assertion SIO_000772 25351246 NP1233192.RAB3xIVwXxlnFT-LkfZes9KxI8_b6hJR5TYxu0SllofaY130_provenance.
- NP1233192.RAB3xIVwXxlnFT-LkfZes9KxI8_b6hJR5TYxu0SllofaY130_assertion wasDerivedFrom befree-2016 NP1233192.RAB3xIVwXxlnFT-LkfZes9KxI8_b6hJR5TYxu0SllofaY130_provenance.
- NP1233192.RAB3xIVwXxlnFT-LkfZes9KxI8_b6hJR5TYxu0SllofaY130_assertion wasGeneratedBy ECO_0000203 NP1233192.RAB3xIVwXxlnFT-LkfZes9KxI8_b6hJR5TYxu0SllofaY130_provenance.